A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

BACKGROUND. Src signaling is markedly upregulated at the invasive glioblastoma (GBM) front following bevacizumab administration. The Src family kinase inhibitor, dasatinib, can effectively block bevacizumab-induced glioma invasion in preclinical models. We hypothesized that combining bevacizumab wit...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer
Prif Awduron: Galanis, Evanthia, Anderson, S. Keith, Twohy, Erin L., Carrero, Xiomara W., Dixon, Jesse G., Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Feathers, Ryan W., Giannini, Caterina, Buckner, Jan C., Anastasiadis, Panos Z., Schiff, David
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788934/
https://ncbi.nlm.nih.gov/pubmed/31290996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32340
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg